期刊文献+

国产地西他滨联合小剂量HAA方案治疗急性髓系白血病的临床观察 被引量:1

下载PDF
导出
摘要 目的 观察国产地西他滨联合小剂量高三尖杉酯碱+阿克拉霉素+阿糖胞苷(HAA方案)治疗急性髓系白血病(AML)的疗效及毒副反应.方法 9例AML患者给予地西他滨15~20mg·m^-2·d^-1静脉滴注d1~3;高三尖杉酯碱2 mg静脉滴注d1~8;阿糖胞苷25 mg皮下注射q12h,d1~8;阿克拉霉素20 mg静脉滴注d1、3、5、7治疗.结果 完全缓解6例(66.7%),部分缓解1例(11.1%),无效2例(22.2%),有效率77.8%,治疗中的毒副反应主要为血液学毒性.结论 国产地西他滨联合小剂量HAA方案治疗AML是一种安全有效的治疗方案,值得推广.
出处 《现代实用医学》 2014年第9期1090-1092,共3页 Modern Practical Medicine
  • 相关文献

参考文献7

  • 1张之赢沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:116-121.
  • 2蔡成森,孙爱宁,仇惠英,何广胜,唐晓文,金正明,傅琤琤,吴德沛.地西他滨单药及联合AAG方案治疗初治急性髓系白血病的临床观察[J].中华临床医师杂志(电子版),2012,6(19):6092-6094. 被引量:13
  • 3Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine adminis- tered daily for 5 days every 4 weeks to ad- ults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial[J]. Journal of Clinical On-cology, 2009, 27(23): 3842-3848.
  • 4Lbbert M, Minden M. Decitabine in ac- ute myeloid leukemia [C]//Seminars in hematology. WB Saunders, 2005, 42(3): $38-$42.
  • 5Cashen A, Shah A, Helget A, et al. A Phase I Pharmacokinetic Trial of Decita- bine Administered as a 3-Hour Infusion toPatients with Acute Myelogenous Leuke- mia (AML) or Myelodysplastic Syndrome (MDS)[C]//ASH Annual Meeting Abstracts. 2005, 106(11): 527.
  • 6Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colony- stimulating factor with low-dose cytosine arabinoside and aclarubicin for previouslytreated acute myelogenous leukemia: a pi- lot study[J]. Leukemia,1995,9(1):10-14.
  • 7急性髓系白血病(复发难治性)中国诊疗指南(2011年版)[J].中华血液学杂志,2011,32(12):887-888. 被引量:92

二级参考文献8

  • 1Kantarjian H,Issa JP,Rosenfeld CS. Decitabine improves patient outcomes in mye1odysplastic syndromes:results of a phaseⅢrandomized study[J].Cancer,2006.1794-1803.
  • 2Ravandi F,Kantarjian H,Giles F. New agents in acute myeloid leukemia and other myeloid disorders[J].Cancer,2004.441-454.
  • 3Herman JG,Baylin SB. Gene silencing in cancer in association with promoter hypermethylation[J].New England Journal of Medicine,2003.2042-2054.
  • 4Issa JP,Gharibyan V,Cortes J. Phase Ⅱ study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate[J].Journal of Clinical Oncology,2005.3948-3956.
  • 5Chowdhury S,Seropian S,Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia[J].American Journal of Hematology,2009.599-600.
  • 6Scandura JM,Roboz GJ. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML[J].Blood,2011.1472-1480.
  • 7Yamada K,Furusawa S,Saito K. Concurrent use of granuloeyte colony-stimulating factor with low-dose cytosine arabinoside and aelarubicin for previously treated acute myelogenous leukemia:a pilot study[J].Leukemia:Official Journal of the Leukemia Society of America,Leukemia Research Fund,U.K,1995.10-14.
  • 8Saito K,Nakamura Y,Aoyagi M. Low dose cytarabine and aclarubicin in combination with granulocyte colony stimulating factor(CAG regimen)for previously treated patients with relapsed of primary resistant acute myelogenous leukemia(AML)and refractory anemia with excess blast in transformation[J].International Journal of Hematology,2000.238-244.

共引文献103

同被引文献10

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部